bioAffinity Technologies (BIAF) EBT (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of EBT data on file, last reported at -$3.6 million in Q1 2026.

• EBT for Q1 2026 came in at -$3.6 million, down 36.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.8 million (down 62.98% YoY), and the FY2025 annual result was -$14.9 million, down 64.66% from the prior year.
• EBT eased to -$3.6 million in Q1 2026 per BIAF's latest filing, from -$3.1 million in the prior quarter.
• Over five years, EBT peaked at -$88052.0 in Q2 2022 and troughed at -$5.0 million in Q3 2025.
• A 5-year average of -$2.6 million and a median of -$2.3 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2023: EBT soared 69.97% in 2022, then tumbled 1871.09% in 2023.
• A 5-year view of EBT shows it stood at -$1.7 million in 2022, then tumbled by 41.58% to -$2.4 million in 2023, then slipped by 25.14% to -$3.0 million in 2024, then dropped by 5.64% to -$3.1 million in 2025, then slipped by 15.84% to -$3.6 million in 2026.
• Business Quant data shows BIAF's EBT at -$3.6 million in Q1 2026, -$3.1 million in Q4 2025, and -$5.0 million in Q3 2025.